权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

SARS-CoV-2 genomic variant surveillance in human and non-human primate populations in Peru

秘鲁人类和非人类灵长类动物种群中的 SARS-CoV-2 基因组变异监测

基本信息

批准号：
10426887
负责人：
Christopher M Barker
金额：
$ 15万
依托单位：
UNIVERSITY OF CALIFORNIA AT DAVIS
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-08-11 至 2022-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10426887
关键词：
2019-nCoV Address Administrative Supplement Amino Acids Animals Award Breeding COVID-19 pandemic Caring Cities Clinical Communities Dental Detection Diagnosis Disease Outbreaks Emerging Communicable Diseases Ensure Epidemiology Factor Analysis Future Genome Genomics Goals Health Health care facility Human Individual Intelligence Investigation Knowledge Libraries Medical Mutation Nomenclature Oral Outcome Parents Patients Peru Peruvian Population Preparation Primates Protocols documentation Recording of previous events Research Risk Factors Rural SARS-CoV-2 antibody SARS-CoV-2 infection SARS-CoV-2 positive SARS-CoV-2 variant Sampling Seroprevalences Severity of illness Surveillance Program Swab Syndrome Testing Travel Variant Virus Work bioinformatics pipeline cohort data sharing demographics experience genetic variant human disease improved instrument mortality nasopharyngeal swab nonhuman primate novel open data pandemic disease programs repository response syndromic surveillance transmission process

项目摘要

ABSTRACT Characterization of SARS-CoV-2 variants in Peru, which has one of the highest mortality rates in the world, has been limited and represents a significant knowledge gap that can be addressed through increased genomic surveillance activities. Located within the Amazon Basin, Iquitos was one of the first cities in Peru to experience the impact of the COVID-19 pandemic with devasting levels of transmission in March 2020, followed by one of the highest documented seroprevalence rates of anti- SARS-CoV-2 antibodies worldwide, only to have a second wave of transmission from January through March 2021. Utilizing human samples collected in and near Iquitos, the EpiCenter for Emerging Infectious Disease Intelligence (EEIDI) will sequence SARS-CoV-2 isolates and characterize variants from Peru and investigate their association with human disease severity and syndromes, reinfection, travel history, health outcomes, and patient demographics. We will also characterize isolates of SARS-CoV-2 variants from sampled animals, in particular non-human primate populations that closely interact with humans to investigate potential for spillback into future animal reservoirs. This work will ensure rapid and adaptive surveillance of existing and emerging variants, while improving an understanding of which variants are most likely to be involved in future outbreaks.

摘要秘鲁的SARS-CoV-2变异体的特征，秘鲁是世界上死亡率最高的国家之一。世界，一直是有限的，代表着一个重大的知识差距，可以通过加强基因组监测活动。伊基托斯位于亚马逊盆地，是这是秘鲁第一批经历COVID-19大流行影响的城市， 2020年3月的传播，其次是有记录的抗- 全球出现SARS-CoV-2抗体，1月起才迎来第二波传播到2021年3月。利用在伊基托斯及其附近收集的人体样本，新兴传染病情报（EEIDI）将对SARS-CoV-2分离株进行测序，表征来自秘鲁的变异体，并研究它们与人类疾病严重程度的关联，综合征、再感染、旅行史、健康结果和患者人口统计学。我们还将从动物样本中分离出SARS-CoV-2变异株，特别是非人灵长类动物与人类密切互动的种群，以研究未来动物的潜在溢出水库这项工作将确保对现有和新出现的变异进行快速和适应性的监测，同时提高对哪些变异最有可能参与未来疫情的理解。